10-Q: Charles River Labs Reports Q2 2026 Results: Net Loss Amidst Divestitures

Charles River Laboratories International, Inc. reported a net loss for the second quarter and first half of 2026, impacted by divestitures and increased tax expenses, though operating income saw an increase.

Summary

• Charles River Laboratories International, Inc. reported a total revenue of $1,004.1 million for the three months ended June 27, 2026, a decrease of 2.7% from $1,032.1 million in the prior year period.
• For the six months ended June 27, 2026, total revenue was $1,999.9 million, a slight decrease of 0.8% from $2,016.3 million in the prior year period.
• The company reported a net loss attributable to common shareholders of $1.5 million for the three months ended June 27, 2026, compared to a net income of $52.3 million in the prior year period.
• For the six months ended June 27, 2026, the net loss attributable to common shareholders was $16.3 million, compared to a net income of $77.8 million in the prior year period.
• Operating income for the three months ended June 27, 2026, increased to $119.9 million (11.9% of revenue) from $100.1 million (9.7% of revenue) in the prior year period.
• Operating income for the six months ended June 27, 2026, increased to $239.8 million (12.0% of revenue) from $174.8 million (8.7% of revenue) in the prior year period.
• The company completed the acquisition of an additional 79% equity interest in PathoQuest SAS for $67.6 million and certain assets of K.F. Cambodia Ltd for $507.3 million in the first half of 2026.
• Divestitures included certain European Discovery Services businesses for $125.2 million and CDMO and Cell Solutions businesses for $12.4 million in the second quarter of 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the reported net loss for the quarter and year-to-date, despite revenue declines being partially offset by divestiture gains and cost management. The significant increase in effective tax rate and ongoing legal proceedings also contribute to a cautious outlook.

Positives

• Operating income increased significantly for both the three-month and six-month periods ended June 27, 2026, driven by gains on asset sales, lower amortization, and reduced legal costs.
• The Manufacturing segment showed a substantial increase in operating income, largely benefiting from the divestiture of the CDMO business.
• The DSA segment's operating income also saw an increase, supported by lower legal costs related to NHP supply chain investigations and reduced restructuring activities.
• The company successfully completed the acquisition of K.F. Cambodia Ltd, a Cambodian NHP supplier, for $507.3 million, integrating it into the DSA and RMS segments.
• The acquisition of PathoQuest SAS was completed, adding to the Manufacturing segment.
• The company repurchased $300.0 million of common stock under its $1.0 billion repurchase program during the first half of 2026, with $700.0 million remaining.
• Revenue from product sales increased by 2.3% for the three-month period.
• The company's backlog for the DSA segment increased slightly to $2.0 billion as of June 27, 2026.

Negatives

• The company reported a net loss attributable to common shareholders of $1.5 million for the three months ended June 27, 2026, and $16.3 million for the six months ended June 27, 2026.
• Total revenue decreased by 2.7% for the three-month period and 0.8% for the six-month period, primarily due to divestitures in the Manufacturing and DSA segments.
• The effective tax rate significantly increased to 101.4% for the three months and 167.0% for the six months ended June 27, 2026, compared to 26.2% and 26.8% respectively in the prior year periods.
• Other (expense) income, net was a significant expense of $37.4 million for the three months and $161.5 million for the six months ended June 27, 2026, largely due to losses on divestitures.
• The company incurred substantial losses on the divestiture of CDMO and Cell Solutions businesses ($63.7 million in Q2 2026, $181.7 million year-to-date).
• Unallocated corporate costs increased by 50.9% for the three-month period and 49.9% for the six-month period, driven by acquisition, integration, and divestiture costs.
• Cash flow from operations decreased to $220.8 million for the six months ended June 27, 2026, from $376.3 million in the prior year period, due to higher variable compensation payments and acquisition-related costs.
• The company's long-term debt, net and finance leases increased to $2,619.9 million as of June 27, 2026, from $2,136.3 million as of December 27, 2025.

Risks

• Ongoing legal proceedings, including a putative securities class action and derivative lawsuits related to non-human primate (NHP) importation practices, continue to pose uncertainty.
• The company faces risks associated with the integration of acquired businesses, such as K.F. Cambodia Ltd and PathoQuest SAS, and the successful execution of divestitures.
• Fluctuations in foreign currency exchange rates can impact financial position, results of operations, and cash flows, with a 10% strengthening of the USD potentially decreasing revenue by $91.6 million and operating income by $21.6 million.
• The company is subject to ongoing tax audits in various jurisdictions, and there are ongoing tax controversies in several countries.
• Macroeconomic conditions and client spending environments, particularly in the DSA segment, could continue to impact demand for services.
• The company's ability to manage its cost structure and achieve projected cost savings of approximately $300 million by the end of 2026 is subject to various factors.
• The company is exposed to market risk from changes in interest rates and currency exchange rates.
• The company's ability to fund operations for the foreseeable future relies on existing cash, cash generated from operations, and access to financing resources.

Future Outlook

The company anticipates continued cautious but improving spending from its client base, particularly in the DSA segment. Cost savings initiatives are expected to generate approximately $300 million in cumulative, annualized cost savings by the end of 2026. The company believes its existing funds, cash flow from operations, and access to financing are sufficient to fund operations for the foreseeable future.

Management Comments

• The company is continuing to implement cost savings initiatives focused on driving greater efficiencies, as well as restructuring actions that have been implemented over the past three years that were focused on workforce right-sizing and site optimization.
• More recently, efficiency initiatives have targeted incremental savings through process improvements, procurement synergies, and implementation of a global business services model.
• The company believes the class action lawsuit to be without merit and plans to vigorously defend against it.
• The company believes the derivative lawsuits to be without merit and plans to vigorously defend against them.

Industry Context

StockSavvy.ai notes that Charles River Laboratories operates in the critical drug discovery and development services sector. The reported results reflect ongoing industry trends of cautious client spending, strategic divestitures of non-core assets (like CDMO and Cell Solutions), and consolidation within the NHP supply chain, evidenced by the acquisition in Cambodia. The company's focus on integrating acquisitions and optimizing its portfolio aligns with broader industry efforts to enhance efficiency and specialized service offerings.

Comparison to Industry Standards

• Charles River Laboratories' revenue decline of 0.8% for the first half of 2026, while concerning, may be viewed in the context of a challenging macroeconomic environment impacting the broader life sciences services sector. Many contract research organizations (CROs) have experienced slower growth or revenue declines due to reduced R&D spending by pharmaceutical and biotech clients.
• The significant increase in operating income as a percentage of revenue (from 8.7% to 12.0% year-to-date) suggests effective cost management and the positive impact of strategic divestitures, which often shed lower-margin businesses. This operational efficiency improvement is a key focus for many CROs aiming to bolster profitability.
• The company's strategic acquisitions, such as the Cambodian NHP supplier, indicate a move towards vertical integration and securing critical supply chains, a trend observed among larger CROs seeking to mitigate supply risks and ensure continuity for clients.
• The reported net loss for the period, while negative, is partially explained by significant one-time charges related to divestitures. Many companies in this sector have faced similar impacts from portfolio restructuring, making direct comparison of net income challenging without adjusting for these non-recurring items.
• The effective tax rate surge to over 100% is an anomaly driven by specific tax impacts of the divestitures and uncertain tax positions, which is not a standard industry benchmark. Normal effective tax rates for companies in this sector typically range from 15-25%.

Legal Proceedings

• A putative securities class action lawsuit filed on May 19, 2023, alleging materially false or misleading disclosures regarding non-human primate importation practices. The case is ongoing after an appeal reversed a prior dismissal.
• A derivative lawsuit filed on November 8, 2023, asserting claims against Board members and officers for breach of fiduciary duties related to disclosures and internal controls concerning NHP importation.
• A second derivative lawsuit filed on August 2, 2024, with similar allegations to the first derivative lawsuit, including insider-trading claims against certain defendants.

Stakeholder Impact

• Shareholders may be impacted by the reported net loss for the period and the ongoing legal proceedings, which introduce uncertainty.
• Employees may be affected by ongoing restructuring and efficiency initiatives, which have included workforce right-sizing actions.
• Clients in the drug discovery and development sector may experience continued cautious spending, although the company's acquisition of NHP suppliers aims to ensure supply chain stability.
• Creditors may note the increase in long-term debt and finance leases, though the company's liquidity is deemed sufficient for the foreseeable future.

Next Steps

• Continue to implement cost savings initiatives focused on driving greater efficiencies.
• Continue restructuring actions focused on workforce right-sizing and site optimization.
• Pursue incremental savings through process improvements, procurement synergies, and implementation of a global business services model.
• Vigorously defend against ongoing litigation.
• Monitor and manage foreign currency exchange rate fluctuations.
• Continue to integrate acquired businesses and optimize the company's portfolio.

Key Dates

Recommendation

The company's performance shows mixed signals. While operating income has improved due to cost controls and strategic divestitures, the reported net loss, increased tax rate, and ongoing litigation create significant headwinds. The company's strategic acquisitions and focus on core services are positive, but the overall financial results and legal uncertainties warrant a cautious 'hold' stance until clearer signs of sustained profitability and resolution of legal matters emerge.

Keywords

drug development, discovery services, safety assessment, research models, non-human primates, manufacturing solutions, biologics testing, microbial solutions